Skip to content

Author

Jia-Bao Wu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Targeting the CAF-LPL-STAT3 axis mitigates osimertinib resistance associated with EGFR downregulation.

BACKGROUND Acquired resistance to osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) arises from both tumor cell-intrinsic pathways and tumor microenvironmental cues. Cancer-associated fibroblasts (CAFs) are critical stromal components that drive therapeutic resistance, yet...

Fei Ye, Jia-Bao Wu, Di Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.